The survey included 87 transgender women receiving services at a L.A. community-based AIDS organization.
Data from the analysis showed a 73% mean reduction in diarrhea episodes from baseline after treatment with Mytesi for 24 weeks.
Previous Phase 3 studies enrolling >4,500 women (ASPIRE and The Ring Study) have already demonstrated the vaginal ring to be safe and effective in protecting women aged 18-45 years against HIV.
Doravirine is being investigated in other Phase 3 trials including DRIVE-AHEAD, DRIVE-FORWARD, and DRIVE-SHIFT.
The early-stage clinical trial studied “mosaic” vaccines created to induce immune responses against various HIV subtypes responsible for infections across the world.
A reservoir of virus incorporated in a small proportion of immune cells was observed but no signs of HIV infection were noted in a 9-year-old child who started anti-HIV therapy at 1 month.
This Phase 2b trial assessed HIV-1 viral suppression with rilpivirine (Janssen) and cabotegravir (ViiV Healthcare) given together every 4 or 8 weeks.
In addition to these studies, bictegravir in combination with FTC/TAF is also being evaluated in two ongoing studies involving virologically suppressed adult patients.
Data from Week 48 previously showed that once-daily Isentress HD achieved the primary efficacy endpoint of non-inferiority vs. twice-daily Isentress.
Want to read more?
Please login or register first to view this content.